Janel Lanphere
21Patents
10h-index
21Co-inventors
71Inventor score
Filing activity: Aug 9, 2002 → Mar 10, 2015
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7842377B2 | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient | Emerging Cross-Sectional Technologies | 120 | Active |
| US7462366B2 | Drug delivery particle | Human Necessities | 64 | Expired |
| US7131997B2 | Tissue treatment | Chemistry; Metallurgy | 49 | Expired |
| US7449236B2 | Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient | Emerging Cross-Sectional Technologies | 38 | Expired |
| US7588780B2 | Embolization | Emerging Cross-Sectional Technologies | 37 | Expired |
| US7963287B2 | Tissue-treatment methods | Human Necessities | 35 | Active |
| US7951402B2 | Drug delivery particle | Human Necessities | 28 | Active |
| US7611542B2 | Tissue treatment | Chemistry; Metallurgy | 20 | Active |
| US7311861B2 | Embolization | Human Necessities | 16 | Expired |
| US7666333B2 | Embolization | Human Necessities | 10 | Active |
| US7727555B2 | Particles | Emerging Cross-Sectional Technologies | 9 | Expired |
| US8012454B2 | Embolization | Human Necessities | 6 | Active |
| US7976823B2 | Ferromagnetic particles and methods | Human Necessities | 5 | Active |
| US9283035B2 | Tissue-treatment methods | Human Necessities | 3 | Active |
| US7858183B2 | Particles | Emerging Cross-Sectional Technologies | 2 | Active |
| US7964123B2 | Embolization | Human Necessities | 1 | Active |
| US8430105B2 | Tissue-treatment methods | Human Necessities | 1 | Active |
| US8273324B2 | Embolization | Human Necessities | 1 | Active |
| US8974829B2 | Embolization | Human Necessities | 0 | Active |
| US9931429B2 | Embolization | Human Necessities | 0 | Active |
| US10675298B2 | Particles | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.